FDA approves Novo Nordisk’s Type 2 diabetes drug for young patients – Novo Nordisk A/S (NYSE:NVO)


Novo Nordisk (NYSE:NVO) says the U.S. Food and Drug Administration approved an expanded indication for its Victoza (liraglutide) injection to lower blood sugar along with diet and exercise in patients aged 10-17 years with Type 2 diabetes.

Victoza was first approved in the U.S. in 2010 to help improve glycemic control in adults with Type 2 diabetes, but it now provides children and adolescents with a new treatment option beyond metformin and insulin.

Type 2 diabetes is the most common form of diabetes, normally occurring in patients 45 years or older, but its prevalence among younger patients has climbed dramatically over the past 20 years.

Source link


Please enter your comment!
Please enter your name here